COLLABORATION AND LICENSE AGREEMENTCollaboration and License Agreement • August 20th, 2018 • Mirati Therapeutics, Inc. • Pharmaceutical preparations • New York
THIS COLLABORATION AND LICENSE AGREEMENT (this “Agreement”) is entered into as of January 7, 2018 (the “Effective Date”) by and among Mirati Therapeutics, Inc., a Delaware corporation, having a place of business at 9393 Towne Centre Drive, Suite 200, San Diego, CA 92121 USA (“Mirati”), MethylGene Inc., a corporation organized under the laws of Canada and the wholly-owned subsidiary of Mirati, having a place of business at 9393 Towne Centre Drive, Suite 200, San Diego, CA 92121 USA (“MethylGene”), and BeiGene, Ltd., a corporation organized under the laws of the Cayman Islands having its principal address at Mourant Ozannes Corporate Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, Cayman Islands KY1-1108 (“BeiGene”). Mirati and BeiGene may be referred to herein individually as a “Party” and collectively as the “Parties.” Mirati and MethylGene may be referred to herein individually as a “Licensor” and collectively as the “Licensors.”
